Dr Michael Yang, an integrative medicine specialist, explores ketamine's clinical use and its role as a psychedelic. They discuss the benefits of inducing awe in patients, the struggle with global theory, and the future of AI. They also touch on suffering as a test for AI and the unique human experience.

Michael Yang is the Senior Managing Partner at OMERS Ventures, with a rich background in health tech investments. He shares insights on the evolving role of product management in the healthcare sector and the shift from aggressive growth to capital efficiency in funding strategies. The discussion touches on the current landscape of M&A activity, challenges faced by health tech startups today, and the types of talent entering the market. Yang also emphasizes the importance of unique value propositions in ensuring successful outcomes in a saturated health tech ecosystem.